Free Shipping on Orders Over $200
The Purest Peptides. Period.
Lab Tested and Shipped from the USA

IPA/TESA Blend

$90.00

Quantity
Discounted Price
5–9
$84.60 each (save $5.40/unit)
10+
$81.00 each (save $9.00/unit)

Quantity

For Research Use Only
Compound Overview
Class Peptide Blend
Also Known As Ipamorelin + Tesamorelin Blend
Purity ≥99%
Amino Acid Sequence Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | Tesamorelin: trans-3-hexenoic acid-modified GHRH(1-44)
Research Areas
Synergistic GH release GHRH/GHSR agonism Pituitary signaling Growth hormone biology

What is IPA/TESA Blend?

The IPA/TESA Blend combines ipamorelin, a selective GH secretagogue receptor (GHSR) agonist, with tesamorelin, a stabilized GHRH analog, in a single research formulation. Like the Ipamorelin + CJC-1295 blend, this combination exploits the well-characterized synergy between GHRH and GHSR signaling pathways at the pituitary. Tesamorelin (trans-3-hexenoic acid modified GHRH 1-44) is an FDA-approved GHRH analog with enhanced stability compared to native GHRH. When paired with ipamorelin, it provides GHRH receptor activation that synergizes with ipamorelin’s GHSR activation for amplified GH release. The key difference from the IPA/CJC blend is the GHRH component — tesamorelin is a full-length 44-amino acid GHRH analog compared to the 29-amino acid CJC-1295 No DAC, and it carries FDA approval for clinical use in HIV-associated lipodystrophy.

Mechanism of Action

The IPA/TESA Blend has been investigated for its dual activation of GHRH receptor and GHSR signaling in pituitary somatotrophs. Tesamorelin activates the GHRH receptor through Gs-coupled adenylyl cyclase signaling, increasing cAMP and activating PKA, which primes GH secretory vesicles. Ipamorelin activates GHS-R1a through Gq-coupled phospholipase C, increasing IP3 and intracellular calcium, which triggers vesicle fusion and exocytosis. Researchers observed that this convergent signaling produces synergistic GH release. Tesamorelin’s trans-3-hexenoic acid modification at the N-terminus protects against DPP-IV cleavage, extending its effective half-life compared to native GHRH. Studies suggest that the full 44-amino acid sequence of tesamorelin may engage additional receptor contacts compared to truncated GHRH analogs. Ipamorelin’s selectivity ensures GH release without cortisol, prolactin, or significant appetite stimulation.

Published Research

Tesamorelin Clinical Data

Falutz et al. (2007) investigated tesamorelin in a randomized clinical trial and demonstrated its ability to stimulate endogenous GH secretion and modulate visceral adipose tissue parameters, establishing the clinical profile of this blend component [1].

GHRH-GHSR Synergy

Bowers et al. (1990) demonstrated the synergistic interaction between GHRH and GH secretagogues at the pituitary level, providing the mechanistic basis for combining tesamorelin with ipamorelin [2].

Ipamorelin Selectivity

Raun et al. (1998) characterized ipamorelin’s selectivity profile, demonstrating GH release without significant cortisol or prolactin co-secretion [3].

Product Specifications

Product IPA/TESA Blend Lyophilized Powder
Available Sizes IPA 5mg / TESA 10mg (15mg)
Purity ≥99% (HPLC verified)
Sequence Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | Tesamorelin: trans-3-hexenoic acid-modified GHRH(1-44)
Appearance White lyophilized powder in glass vial
Storage Store lyophilized at -20°C. Reconstituted solution at 2-8°C, use within 14 days.
Testing Third-party tested — Certificate of Analysis available

Frequently Asked Questions

The IPA/TESA Blend combines ipamorelin (GHSR agonist) with tesamorelin (GHRH analog) for synergistic GH secretagogue research.

The GHRH component differs u2014 tesamorelin is a full 44-amino acid GHRH analog with FDA approval, while CJC-1295 No DAC is a 29-amino acid modified GHRH fragment.

Store lyophilized at -20°C. Once reconstituted, store at 2-8°C and use within 14 days.

Tesamorelin is a stabilized GHRH(1-44) analog with a trans-3-hexenoic acid modification. It is FDA-approved for clinical use and stimulates endogenous GH secretion.

Yes, both Ipamorelin and Tesamorelin are available as individual products.

References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338
  2. Bowers CY, et al. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1990;128(4):2027-2035.
  3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822

Customer Reviews

4.9
Based on 11 reviews
M
Morgan P. Verified Feb 28, 2026

Quick delivery and the quality is consistently high.

S
Skyler M. Verified Jan 2, 2026

This vendor sets the standard. Highly recommend.

M
Matthew M. Verified Dec 27, 2025

This vendor sets the standard. Highly recommend.

H
Heather J. Verified Dec 24, 2025

Impressed with the quality. Packaging was professional.

A
Alex S. Verified Dec 12, 2025

Outstanding quality. This is my go-to source now.

A
Amanda N. Verified Nov 12, 2025

Great product. Arrived quickly and exactly as described.

M
Megan J. Verified Nov 10, 2025

Great product. Arrived quickly and exactly as described.

D
Drew C. Verified Nov 7, 2025

Outstanding quality. This is my go-to source now.

T
Tyler P. Verified Oct 5, 2025

Solid product quality. COA checks out perfectly.

R
Ryan J. Verified Oct 2, 2025

Exactly what I needed for my research. Clean product.

M
Marcus J. Verified Sep 26, 2025

Product is great. Only minor delay in shipping.

IPA/TESA Blend 10mg 5mg
You're viewing: IPA/TESA Blend $90.00
Select options
Your Cart

Your cart is empty

Browse Products

Product Index